Patrick Daly

Cancer Nursing Today nonprod

Robert E. Brown, MD, and collaborating researchers from the University of Texas Health Science Center at Houston McGovern Medical School in Houston, used morphoproteomics, a holistic approach to characterizing diseased cells, to reveal commonalities in the biology of patients with diffuse large B-cell lymphoma (DLBCL). According to the researchers&rsquo; report, published in Annals of Clinical and Laboratory Science, their analysis suggested that the SIRT1 (silent mating type information regulation 2 homolog 1), EZH2 (enhancer of Zeste homolog 2), and CXCR4 (C-X-C chemokine receptor 4) pathways could be effective avenues to target the biology of DLBCL.The investigators performed a morphoproteomics analysis on a tissue sample microarray from nine cases of classic DLBCL, including the use of &ldquo;immunohistochemical probes&rdquo; to detect SIRT1, EZH2, CXCR4, &ldquo;and their cellular compartmentalization by bright field microscopy.&rdquo;According to the report, the researchers detected of SIRT1 and EZH2 expression in a majority of tumoral nuclei for eight and nine cases of DLBCL, respectively. Additionally, the expression of CXCR4 was seen in &ldquo;the cytoplasmic and/or plasmalemmal compartment at &gt;50% of the tumor cells in all nine cases of DLBCL,&rdquo; they reported. The findings on SIRT1 and EZH2 expression in DLBCL were largely consistent with morphoproteomic findings in B-cell acute lymphoblastic leukemia (ALL), a concordance which had &ldquo;pharmacogenomic and therapeutic implications,&rdquo; according to the authors.Overall, Dr. Brown and colleagues closed with the opinion that targeting SIRT1, EZH2, and CXCR4 pathways with &ldquo;relatively non-toxic adjuvant therapeutic agents such as metformin, melatonin, curcumin, sulforaphane, vitamin D3, and plerixafor,&rdquo; could be effective in the treatment of DLBCL.

Role of SIRT1, EZH2, and CXCR4 Pathways in Treating Diffuse Large B-Cell Lymphoma

Lymphoma

Robert E. Brown, MD, and collaborating researchers from the University of Texas Health Science Center at Houston McGovern Medical School in Houston, used morphoproteomics, a holistic approach to characterizing diseased cells, to reveal commonalities in the biology of patients with diffuse large B-cell lymphoma (DLBCL). According to the researchers’ report, published in Annals of Clinical [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe